This information is intended for healthcare professionals based in Ireland.


ELIQUIS® is indicated in the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).1

ARISTOTLE is a randomized, double-blind trial, where ELIQUIS® (at a dose of 5 mg twice daily in 95.3% of patients) was compared with warfarin (target international normalized ratio, 2.0 to 3.0) in 18,201 patients with atrial fibrillation and at least one additional risk factor for stroke. The primary outcome was ischaemic or haemorrhagic stroke or systemic embolism. The trial was designed to test for noninferiority, with key secondary objectives of testing for superiority with respect to the primary outcome and to the rates of major bleeding and death from any cause. The median duration of follow-up was 1.8 years.2

AVERROES is a double-blind study in which 5599 patients with atrial fibrillation who were at increased risk for stroke and for whom vitamin K antagonist therapy was unsuitable were randomly assigned to receive ELIQUIS® (at a dose of 5 mg twice daily in 94% of patients) or ASA (Acetylsalicylic Acid) (81 to 324 mg per day), to determine whether ELIQUIS® was superior. The mean follow up period was 1.1 years. The primary outcome was the occurrence of stroke or systemic embolism. The data and safety monitoring board recommended early termination of the study because of a clear benefit in favour of ELIQUIS®.3

Learn more about dosing in NVAF

For full information on therapeutic indications, please visit SmPC

Risk Minimisation Materials

The Eliquis (apixaban) Prescriber Guide and Patient Alert Card are risk minimisation materials developed for all indications as an aid to prescribing, in particular they are aimed at increasing awareness about the potential risk of bleeding during treatment with apixaban and providing guidance on how to manage that risk. Printed copies of these educational materials may be obtained by contacting the Bristol-Myers Squibb Medical Information Department (telephone: 1800 749 749; e-mail: Alternatively, electronic copies can be accessed via the HPRA website at


  1. ELIQUIS® (apixaban) Summary of Product Characteristics.
  2. Granger CB, Alexander JH, McMurray JJ. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med 2011;365:981-992.
  3. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. New Engl J Med 2011;364:806-817.